INTRODUCTION
For the individual and population benefits of treatment to be realized, the time from HIV infection to durable viral suppression (DVS) must be minimized, which requires early diagnosis, linkage to medical care, and consistent access and adherence to antiretroviral treatment (ART). [1] [2] [3] [4] [5] Many persons living with HIV (PLWH), however, may not achieve viral load suppression (VLS) or DVS as a result of difficulties accessing medical care and/or initiating and adhering to treatment. Nationally, one-third of persons receiving HIV medical care in 2011 did not have DVS over a 2-year period (2012-2013) and had persistent viremia at levels associated with HIV transmission (.1500 copies/mL). 6 These data underscore the need for interventions that support consistent ART adherence.
The New York City (NYC) Ryan White Part A HIV Care Coordination Program (CCP) uses multiple strategies to promote care and treatment engagement among Ryan White clients at risk of poor HIV care outcomes (eg, nonadherence to ART). 7, 8 Previous work has demonstrated that the CCP increases short-term VLS when comparing an individual's year before with year after program enrollment. 7, 8 However, this previous work did not assess longer-term CCP effectiveness (ie, more than 12 months after enrollment). Furthermore, VLS among all NYC residents in HIV medical care improved annually from 2009 to 2016 and in tandem with populationbased HIV treatment strategies [eg, the recommendation that all PLWH initiate ART at diagnosis, regardless of CD4 + lymphocyte count (CD4)]. 9-11 The pre-post effectiveness evaluations do not isolate program effects from these secular changes or address longer-term effectiveness.
We therefore aimed to compare DVS among CCP enrollees with DVS in a contemporaneous, non-CCPexposed comparison of HIV patients, and to describe CCP enrollees who did not experience DVS.
METHODS

Intervention Description
In December 2009, with Ryan White Part A funding, the NYC Department of Health and Mental Hygiene (DOHMH) launched the CCP. The intervention has previously been described, and program materials are available on the DOHMH web site. 7, 8, [12] [13] [14] CCP protocols permit enrollment of HIV-infected adults or emancipated minors who are eligible for local Ryan White Part A services (based on residence within the New York grant area and household income ,435% of federal poverty level) and who are (1) newly diagnosed with HIV; (2) never in care or lost to care for $9 months; (3) irregularly in care or often missing appointments; (4) starting a new ART regimen; (5) experiencing ART adherence barriers; or (6) manifesting treatment failure or ART resistance. 8 The CCP combines various evidence-based elements, including case management by interdisciplinary care teams, patient navigation, and structured health promotion, and was rolled out as a service program without a designated comparison group.
Data Sources
We retrospectively created an observational cohort of persons enrolled and not enrolled in the CCP by merging longitudinal population-based surveillance and programmatic data sources. CCP programmatic data were drawn from the DOHMH Electronic System for HIV/AIDS Reporting and Evaluation. The HIV Surveillance Registry ("the Registry") contains demographic and clinical information on all diagnoses of HIV reported in NYC, as well as comprehensive HIVrelated laboratory reporting [including all CD4 and VL results for individuals who have received HIV medical care in NYC]. 15 Vital status information is updated through regular matches with death data. 11 Using programmatic data, we identified all persons who enrolled in the CCP from December 1, 2009, to March 31, 2013 , and excluded clients who died within 12 months of program enrollment (N = 279). Using Registry data, we identified all persons who were diagnosed with HIV as of March 31, 2013 , and 18 years or older at diagnosis. This study was approved by the institutional review board at (redacted for review). For these secondary analyses of deidentified data, we received a waiver of informed consent under 45 CFR 46.116(d) (2) .
Constructing a Contemporaneous Comparison Group
We merged programmatic data with Registry data to identify non-CCP persons who were potentially eligible for inclusion in the comparison group, through a 4-step process ( Fig. 1-left column) . Our approach has been described elsewhere and can be summarized as follows (see Appendix 1, Supplemental Digital Content, http://links.lww.com/QAI/ B225 for full details on the 4-step process). 12 First, to identify non-CCP PLWH who could have been enrolled in the CCP, we created CCP eligibility windows: For persons who died, we closed their eligibility windows $12 months before the date of death, to ensure comparability with the CCP group. For a description of the Registry-based eligibility criteria and enrollment eligibility windows, see Table 1 , Supplemental Digital Content, http://links.lww.com/ QAI/B225. Second, we randomly assigned non-CCP PLWH a pseudo-enrollment date that fell within their eligibility window(s); this was the time point used to start follow-up and outcome assessment. The temporal distribution of dates among the non-CCP PLWH matched that of the enrollment dates among CCP enrollees.
Third, we restricted to persons who had $1 VL in months 0-12 after enrollment/pseudo-enrollment and $2 VLs in months 13-36. We required a minimum number of VLs as a proxy for ongoing receipt of NYC HIV medical care to prevent a differential (non-CCP versus CCP) effect of outmigration, which we suspected to have occurred more frequently among non-CCP than CCP persons, as CCP enrollment and services require residence in NYC.
Finally, we matched CCP enrollees to the non-CCP PLWH on enrollment/pseudo-enrollment date, baseline treatment status, and propensity for CCP enrollment. The 4 baseline treatment status groups were defined in terms of diagnosis or VLS in the 12 months before enrollment/ pseudo-enrollment: (1) newly diagnosed, (2) consistently suppressed ($2 VLs $90 days apart and all VLs #200 copies/mL), (3) no evidence of VLS (all VLs reported .200 copies/mL or lacking any VL report), or (4) inconsistently suppressed ($1 VL #200 copies/mL, but not all VLs #200 copies/mL).
Outcome Definitions
The follow-up period extended from December 1, 2009, to March 31, 2016 , which allowed for 36 months of follow-up. We defined DVS as regular VL monitoring and all VLs #200 copies per milliliter in months 13-36 of followup. 6 We excluded months 0-12 from the definition of DVS to allow 1 year for all members of the cohort to establish medical care. Regular VL monitoring was defined as having $1 VL in each 12-month period of follow-up and $90 days between the first and the last VL reported during months 13-36. For persons known to have died, regular VL monitoring was defined as having $1 VL result in each 12-month period of follow-up for which they were alive. To assess differences in treatment outcomes beyond those that might be explained primarily by low-level viremia, we examined DVS at a higher VL threshold of 1500 copies per milliliter. We chose thresholds in recognition of clinical guidelines for individual health (#200 copies/mL) and for minimizing risk of HIV transmission (#1500 copies/mL). 16 Because persons with more VL monitoring have more opportunities to fail the DVS measure, we also examined DVS using the 200 threshold and the first and last VL reported during months 13-36.
For context as to ART access/uptake, we examined the outcome of ever having VLS after enrollment (defined as $1 VL #200 copies/mL in the 36 months after enrollment/ pseudo-enrollment).
Covariates
Among CCP enrollees, we used demographic, clinical, and psychosocial characteristics collected at the time of CCP enrollment to examine predictors of not having DVS. Unstable housing was defined as homelessness, reliance on temporary or transitional housing, residence in institutional housing, or residence in someone else's unit with the expectation of staying fewer than 6 months. Recent drug use was defined as self-reported use of heroin, cocaine/crack, methamphetamine, or prescription drugs for recreational purposes during the 3 months before enrollment. Mood disorder was defined as a self-reported mental health diagnosis related to depression, bipolar disorder, or other mood disorders. Heart disease was defined as a self-reported diagnosis of heart disease, hypertension, or high blood pressure. We selected these variables because they were either standard demographics or important predictors of improved VLS in our single-group, pre-post estimates of CCP effectiveness. 7, 8 Length of CCP enrollment was measured as the number of days from the date of enrollment to the earlier of: program drop-out or graduation, death, or March 31, 2016.
Statistical Analysis
Through an intention-to-treat approach, we examined the effectiveness of the CCP on DVS or ever experiencing VLS. We used a log binomial regression model, accounting for the matched design, and modeled within each baseline treatment status group and overall. To describe predictors of not experiencing DVS among CCP enrollees, we used logistic regression and included all variables in Table 1 in the final adjusted model. To assess whether DVS increased with duration in the CCP, we characterized DVS by length of enrollment and used the Cochran-Armitage test for trend.
All analyses were conducted in SAS Version 9.3 (Cary, NC).
RESULTS
From December 1, 2009, to March 31, 2013, 7337 persons enrolled in the CCP, of whom 7058 (96%) were alive 12 months after enrollment; 87% (6385) of CCP enrollees had evidence of medical care in NYC. Of the 62,828 persons who seemed eligible but were not enrolled in the CCP, 92% (57,746) were assigned a pseudo-enrollment date; 59% (37,108) had evidence of care in NYC, and 10% were 1:1 propensity-matched to a CCP enrollee (6207 in non-CCP and 6207 in CCP). Thus, 85% (6207/7337) of all persons enrolling in the CCP were included in this analysis (Fig. 1) .
The matched CCP and non-CCP PLWH were similar on measured characteristics: 64% were males, 92% were non-Latino black or Latino, 50% were aged 45 years or older, and 29% were reported as men who have sex with men (MSM) ( Table 2 ). Most (68%) of the cohort came from NYC neighborhoods with the highest poverty rates and the highest HIV prevalence rates. At enrollment/pseudoenrollment, 32% had a VL #200 copies per milliliter and 32% had CD4 ,200 cells/mL. In the year before enrollment/ pseudo-enrollment, 15% were newly diagnosed, 15% were consistently virally suppressed, 41% had no evidence of VLS, and 29% were inconsistently suppressed. Among CCP enrollees, 22% were homeless or unstably housed, 45% had less than a high school education, 81% were unemployed, 15% reported recent drug use, and 39% reported a mood disorder at baseline (data not shown). Similar information was not available for non-CCP PLWH. Among CCP enrollees and non-CCP PLWH, most (90%) had $1 VL #200 copies per milliliter in the 36 months after enrollment/pseudo-enrollment (Table 3) . However, only 37% of the cohort experienced DVS in that period, and the proportion varied greatly by baseline treatment status: 71% among the consistently suppressed, 53% among the newly diagnosed, 35% among the inconsistently suppressed, and 20% among persons with no evidence of VLS before enrollment/pseudo-enrollment. Using the transmissibility threshold of 1500 copies per milliliter, 48% had DVS or approximately 10% more individuals within each baseline treatment status group. Using the first and last VL and the threshold of 200 copies per milliliter, 49% had DVS; the proportion succeeding in each baseline treatment status group was similar to DVS using the 1500 threshold (Table 3) . CCP enrollees with no evidence of VLS in the year before enrollment were significantly more likely to have DVS when compared with their non-CCP counterparts [relative risk (RR): 1.16; 95% confidence interval (CI): 1.04 to 1.29] . CCP enrollees with inconsistent evidence of VLS were significantly less likely to have DVS when compared with their non-CCP counterparts (RR: 0.87; 95% CI: 0.79 to 0.95). For persons newly diagnosed or always suppressed in the year before enrollment/pseudo-enrollment, there was no CCP versus non-CCP DVS difference. The RRs estimated using the 1500 copies per milliliter threshold were nearly identical to the RRs for the 200 copies per milliliter threshold (Table 3) . Using the first and last VL, the effect favoring CCP among the no evidence of the VLS group remained significant (RR: 1.17; 95% CI: 1.07 to 1.27), and no CCP versus non-CCP difference was observed among the newly diagnosed or persons with consistent or inconsistent suppression.
A majority of CCP enrollees remained in the program for .365 days (64% of CCP enrollees, median days enrolled 540, interquartile range 254-1094 days). Persons newly diagnosed or always suppressed were enrolled longer than persons with no evidence of VLS or inconsistent VLS (median days enrolled: 653, 644, 496, and 500, respectively). DVS increased with enrollment duration, for all groups other than those consistently suppressed at baseline (Table 4) .
Regular VL monitoring was absent for only 2% of CCP enrollees (69/3937) and 3% of non-CCP PLWH (104/3810), meaning that failures on DVS were nearly always (98%) due to $1 VL surpassing the 200 copies per milliliter threshold. A VL .200 at CCP enrollment was the greatest predictor of lacking DVS in months 12-36; specifically, persons with a baseline VL of 201-1499 copies per milliliter or .1500 copies per milliliter had $3.5 times the odds of lacking DVS, when compared with persons who were virally suppressed at enrollment [odds ratio (OR) 3.51; 95% CI: 2.86 to 4.31 and OR 3.72; 95% CI: 3.24 to 4.27, respectively].
DISCUSSION
NYC PLWH have experienced substantial improvements in VLS over time, likely driven by advances in ART tolerability, increased treatment access, implementation of population-based HIV prevention strategies, and a robust system of medical and nonmedical services for PLWH. 10, 11, 17 Despite these resources and availability of the CCP intervention itself, during 36 months of follow-up, ,40% of the analytic cohort experienced DVS. When we examined DVS at the threshold of 1500 copies per milliliter, a likely threshold for transmissibility, 16 under half the cohort achieved DVS. Importantly, almost everyone accessed HIV care and treatment during the follow-up period, given that 90% of the total cohort had at least one-time VLS and few persons (,3%) lacked regular VL monitoring. These findings underscore a substantial need for sustained, and perhaps more intensive, adherence support in this vulnerable population with multiple barriers but with high treatment access and uptake.
Among persons with no evidence of VLS in the year before baseline (the largest baseline treatment status group, at 41% of the matched cohort), we observed a 16% increase in DVS for CCP enrollees over non-CCP PLWH. This is consistent with our findings on VLS at 12 months and suggests the program should prioritize previously unsuppressed individuals for enrollment. 7, 8, 12 We did not observe a CCP effect on DVS among newly diagnosed enrollees. The newly diagnosed were the second most likely group to achieve DVS and were entering a service landscape with simpler and more tolerable drug regimens and an increased emphasis on early treatment, as compared to NYC PLWH who were diagnosed in previous decades. At this stage in the epidemic, persons who are newly diagnosed in NYC may have an easier time with VLS over the long term, regardless of CCP enrollment.
We unexpectedly observed lower DVS among CCP enrollees versus non-CCP PLWH who were inconsistently suppressed in the year before enrollment/pseudo-enrollment. The CCP model may perform better at connecting or reconnecting persons with HIV care and treatment than at promoting consistent, long-term treatment success among those who have already (and in the past year) experienced some treatment success. In previous analyses, the inconsistently suppressed CCP enrollees were no more likely to achieve VLS at 12 months than a contemporaneous non-CCP-exposed group (62.2% of CCP with VLS versus 62.3% of non-CCP with VLS, RR = 0.99; 95% CI: 0.95 to 1.05). 12, 18 We suspect the CCP may have had a null effect on DVS among the inconsistently suppressed; however, we observed a negative effect in this group, which we attribute to more frequent VL monitoring. In all baseline treatment status groups, the CCP enrollees had 1 more VL test on average during follow-up than non-CCP PLWH (eg, inconsistently suppressed CCP enrollees, mean number of VL during follow-up: 7.3, and for inconsistently suppressed non-CCP PLWH: 6.3). More VL monitoring results in more opportunities to fail the DVS measure and consequently more conservative CCP effect estimates, in all baseline groups. However, more frequent VL monitoring may be more likely to negatively bias results among the inconsistently suppressed because this group is defined by its pattern of unstable treatment outcomes, with low and high VL values in the year before enrollment. In support of this explanation, when we examined DVS and ever suppression (ie, metrics based on the same number of VL reports in the CCP and non-CCP groups), we observed no difference in outcomes between CCP and non-CCP PLWH with inconsistent suppression at baseline. The low proportion of PLWH who achieved DVS, regardless of program enrollment and despite high levels of VL monitoring, is concerning, as the health of individual patients and the success of HIV prevention efforts are determined primarily by the ability to maintain long-term adherence to ART. [1] [2] [3] [4] 19 Except for persons who were consistently suppressed before enrollment/ pseudo-enrollment, our cohort of vulnerable clients, not surprisingly, demonstrated lower success on DVS over a 2-year period than the 62% estimate from a national cohort of recently diagnosed PLWH receiving medical care. 6 The best predictor of not having DVS was an unsuppressed baseline VL, which may be indicative of longstanding difficulties with medical care and/or other major barriers to treatment adherence.
DVS increased with length of enrollment in the program for all groups except the consistently suppressed. However, the increase among the CCP enrollees does not necessarily translate to an improved CCP effect relative to non-CCP. First, a majority were CCP enrolled for $365 days; thus, the proportion with DVS overall is weighted toward the proportion with DVS among those enrolled for $365 days. Second, as a sensitivity analysis, we examined DVS among CCP enrollees who were enrolled for $365 days versus their matched pairs. This showed a positive CCP effect among the group with no evidence of suppression (25% with DVS in CCP versus 18% with VLS in non-CCP; RR = 1.39, 95% CI: 1.22 to 1.60) and a null CCP effect in the other 3 baseline groups. Thus, relative to non-CCP, the results from the sensitivity analysis remain the same as results from the intention-to-treat analyses. Notably, however, given that we balanced propensity scores in the overall group, this sensitivity analysis is subject to confounding beyond that in the intention-to-treat analyses.
Case management interventions vary significantly in design and target population, making cross-study comparisons difficult. 20 Randomized trials of case management interventions have not evaluated VLS outcomes; however, data from trials suggest that case management (versus usual care) results in improved linkage to care and retention in HIV medical care. [21] [22] [23] Cohort studies of case management interventions have evaluated VLS outcomes and reported null results among the general Ryan White population or among marginally housed PLWH. 23, 24 Notably, these cohort studies did not present results stratified by baseline VLS status or examine VLS beyond the first year.
Our study has several limitations. First, to control for confounding, we were limited to variables available in the Registry, as the common data source. Second, we were not able to account for service delivery models received by non-CCP PLWH. Third, we did not include persons who died in the first 12 months after enrollment. The CCP aims to enroll persons most at risk of poor HIV outcomes, including those for whom the intervention may represent a last attempt to avert mortality. There is no analogous entry point for non-CCP PLWH, as pseudo-enrollment date assignment is random. To increase the comparability of CCP with non-CCP groups, we required individuals have $12 months of observation beyond their pseudo-enrollment/enrollment. Fourth, we restricted this analysis to individuals with $3 VL tests during the 36 months of follow-up. As a result, persons with no surveillance-based evidence of care after enrollment/ pseudo-enrollment were excluded. However, investigations in NYC and other metropolitan areas suggest that laboratory reports to HIV surveillance underestimate the proportion engaged in care or virally suppressed, due to outmigration. [25] [26] [27] [28] [29] [30] [31] In examinations of short-term VLS (within 12 months of enrollment), this restriction resulted in more conservative estimates of any CCP effect, and we suspect this restriction would also result in more conservative DVS estimates, given that longer follow-up allows more time for outmigration.
The strengths of our study include the use of a populationbased data source to derive the observational comparison group and to measure longitudinal outcomes. Thus, outcome data were available regardless of care location or duration of intervention enrollment. As a result, we had $3 years of follow-up on all persons who were alive at the end of follow-up (95% of the overall cohort), and we were able to examine different VL Total N (%) % DVS* Total N (%) % DVS* Total N (%) % DVS* Total N (%) % DVS* Total N (%) % DVS* outcomes and thresholds. Finally, annual citywide improvements in VLS have occurred in tandem with advances in population-based HIV treatment strategies. A strength of our contemporaneous comparison group approach is that matching on enrollment/pseudo-enrollment dates isolates program effects from secular improvements in VLS. 12 In this intent-to-treat analysis, the CCP showed an effect on DVS among those previously unsuppressed in the 12 months before CCP enrollment, who constituted the largest baseline clinical status group (41% of our cohort). People without evidence of VLS should be prioritized for CCP enrollment over those with recent evidence of VLS. During 36 months of follow-up, 90% of the cohort had onetime VLS, but ,40% of the cohort experienced DVS. These findings underscore the need for more intensive efforts to sustain adherence over time among persons with a history of poor HIV care outcomes and a high prevalence of major barriers, in a context of high treatment access/uptake.
